Free Trial
NASDAQ:VVOS

Vivos Therapeutics (VVOS) Stock Price, News & Analysis

Vivos Therapeutics logo
$3.83 -0.04 (-1.03%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$3.76 -0.08 (-1.96%)
As of 04:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Vivos Therapeutics Stock (NASDAQ:VVOS)

Key Stats

Today's Range
$3.66
$4.23
50-Day Range
$2.08
$3.87
52-Week Range
$1.97
$6.28
Volume
1.14 million shs
Average Volume
584,923 shs
Market Capitalization
$22.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.82
Consensus Rating
Moderate Buy

Company Overview

Vivos Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

VVOS MarketRank™: 

Vivos Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 720th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vivos Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Vivos Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Vivos Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Vivos Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.43) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vivos Therapeutics is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vivos Therapeutics is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vivos Therapeutics has a P/B Ratio of 2.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Vivos Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.17% of the float of Vivos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vivos Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vivos Therapeutics has recently increased by 0.56%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Vivos Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Vivos Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.17% of the float of Vivos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vivos Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vivos Therapeutics has recently increased by 0.56%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Vivos Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Vivos Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for VVOS on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Vivos Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vivos Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.00% of the stock of Vivos Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 26.35% of the stock of Vivos Therapeutics is held by institutions.

  • Read more about Vivos Therapeutics' insider trading history.
Receive VVOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VVOS Stock News Headlines

Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
See More Headlines

VVOS Stock Analysis - Frequently Asked Questions

Vivos Therapeutics' stock was trading at $4.29 on January 1st, 2025. Since then, VVOS stock has decreased by 10.7% and is now trading at $3.83.
View the best growth stocks for 2025 here
.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.01. The company earned $3.70 million during the quarter, compared to analyst estimates of $3.63 million. Vivos Therapeutics had a negative net margin of 76.82% and a negative trailing twelve-month return on equity of 170.43%.
Read the conference call transcript
.

Vivos Therapeutics shares reverse split on the morning of Friday, October 27th 2023.The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Vivos Therapeutics (VVOS) raised $20 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 3,300,000 shares at $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.

Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vivos Therapeutics investors own include Meta Platforms (META), NIO (NIO), Pfizer (PFE), Plug Power (PLUG), Advanced Micro Devices (AMD), Aridis Pharmaceuticals (ARDS) and Cocrystal Pharma (COCP).

Company Calendar

Last Earnings
5/15/2025
Today
7/03/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:VVOS
Fax
N/A
Employees
160
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.82
High Stock Price Target
$6.20
Low Stock Price Target
$2.25
Potential Upside/Downside
+25.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.14 million
Pretax Margin
-76.82%

Debt

Sales & Book Value

Annual Sales
$15.03 million
Price / Cash Flow
N/A
Book Value
$1.35 per share
Price / Book
2.84

Miscellaneous

Free Float
5,713,000
Market Cap
$22.56 million
Optionable
Optionable
Beta
7.01
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:VVOS) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners